



EUROPEAN SOCIETY OF PERITONEAL SURFACE ONCOLOGY



THE EUROPEAN SOCIETY
OF SURGICAL ONCOLOGY



esso
THE EUROPEAN SOCIETY
OF SURGICAL ONCOLOGY



ESSO-ESPSO, ISPSM & AGOI

3rd INTERNATIONAL COURSE

WORKSHOP & CONFERENCE ON PERITONEAL SURFACE MALIGNANCIES
YEAR IN REVIEW: GYNECOLOGIC ONCOLOGY | COLORECTAL CANCER





Early Bird Registration
Extended till 15 April, 2019

Abstract Submission
Extended till 12 April, 2019

19 - 21 April 2019

R D Choksi Auditorium,
Tata Memorial Hospital,
Parel, Mumbai





EUROPEAN SOCIETY OF PERITONEAL SURFACE ONCOLOGY



3rd INTERNATIONAL COURSE

WORKSHOP & CONFERENCE ON PERITONEAL SURFACE MALIGNANCIES YEAR IN REVIEW: GYNECOLOGIC ONCOLOGY | COLORECTAL CANCER

19 - 21 April 2019, Mumbai

Dear Friends,

It is our pleasure to invite you to the 3rd ESSO-ESPSO, ISPSM & AGOI International Course, Workshop & Conference along with Year in Review in Gynecological and Colorectal malignancies, organized by the Indian Society of Peritoneal Surface Malignancies (ISPSM) in collaboration with the Association of Gynaecologic Oncologists of India (AGOI), April, 19 - 21 at Tata Memorial Hospital, Mumbai.

The scientific program has been carefully designed to present and discuss the most recent evidence in peritoneal surface malignancies and to review important developments in fields of gynecological and colorectal cancers in last one year. The pre-conference workshop will have a series of lectures covering practical aspects of CRS & HIPEC followed by live surgical demonstration of CRS, HIPEC and PIPAC. The first twenty delegates will also get an opportunity to get hands-on in wet lab.

The conference will feature keynote lectures, didactic sessions, panel discussions and satellite symposia. Delegates will get a chance to meet and interact with renowned international and national faculty members. The conference will also provide an opportunity to present original work during oral and poster presentation sessions with exciting awards in both categories. The best oral and poster awardees will receive international HIPEC travel fellowships to an European Centre under the guidance of an international faculty.

This conference is intended for gynecological, surgical and medical oncologists, oncology nurses and technicians, perfusionists, pathologists and other healthcare professionals working in the field of gynecological and gastrointestinal cancers.

We look forward to your active participation & support in making this meeting successful.

Regards

**Dr. Sudeep Gupta
Organising Chairman**

**Dr. Amita Maheshwari
Organising Secretary**

**Dr. Avanish Saklani
Co-Organising Secretary**

**Dr. SVS Deo
President, ISPSM**

**Dr. Somashekhar SP
Hon. Secretary, ISPSM**

**Dr. Shalini Rajaram
President, AGOI**

**Dr. Manish Bhandare & Dr. Vikram Chaudhari
Workshop Co-ordinators**



EUROPEAN SOCIETY OF PERITONEAL SURFACE ONCOLOGY



3rd INTERNATIONAL COURSE

WORKSHOP & CONFERENCE ON PERITONEAL SURFACE MALIGNANCIES YEAR IN REVIEW: GYNECOLOGIC ONCOLOGY | COLORECTAL CANCER

19 - 21 April 2019, Mumbai

INTERNATIONAL FACULTY



Dr. Vic Verwaal

HIPEC Specialist,
Department of GI Surgery
Aarhus University hospital,
Denmark



Dr. Vahan Kepenekian

Department of Surgical Oncology
CHU Lyon Sud, University of Lyon,
France




Dr. Kusamura Shigeki

HIPEC Specialist,
IRCCS Foundation National
Cancer Institute, Milan,
Italy



Dr. Henk Schreuder

Ass. Professor MD, PhD,
Gynaecologies Oncologist at
University Medical Center,
Utrecht, Netherlands



EUROPEAN SOCIETY OF PERITONEAL SURFACE ONCOLOGY



THE EUROPEAN SOCIETY
OF SURGICAL ONCOLOGY



esso
THE EUROPEAN SOCIETY
OF SURGICAL ONCOLOGY



3rd INTERNATIONAL COURSE

WORKSHOP & CONFERENCE ON PERITONEAL SURFACE MALIGNANCIES YEAR IN REVIEW: GYNECOLOGIC ONCOLOGY | COLORECTAL CANCER

19 - 21 April 2019, Mumbai

ISPSM Members

International Founding Members & Patrons

- Dr. Aviram Nissan
- Dr. Olivier Glehen
- Dr. Marcello Deraco
- Dr. Vic Verwaal
- Dr. Ignace de Hingh
- Dr. Kusamura Shigeki
- Dr. Pompiliu Piso


National Council Members

- Dr. SVS Deo
- Dr. Somashekhar S P
- Dr. Shabber Zaveri
- Dr. Avanish Saklani
- Dr. Harit Chaturvedi
- Dr. Vikash Mahajan
- Dr. Mahesh B
- Dr. Shivendra Singh
- Dr. Kapil Kumar
- Dr. Rama Joshi
- Dr. Amith Rauthan
- Dr. Amita Maheshwari
- Dr. Ashwin Rajagopal
- Dr. Ganesh MS
- Dr. Ayappan
- Dr Subramanyeshwar rao

AGOI Executive Committee

- Dr. Kasturi Lal
- Dr. S.B.L.Shrivastav
- Dr. Amrit Gupta
- Dr. Shalini Rajaram
- Dr. Uma Singh
- Dr. Geetha Nagasree
- Dr. Amita Maheshwari
- Dr. Jita Parja
- Dr. Nisha Singh
- Dr. Vijay Ahuja
- Dr. Sabhyata Gupta
- Dr. Ranu Patni
- Dr. Richa Chauhan
- Dr. Vinita Singh
- Dr. Janmejaya Mohapatra
- Dr. Satinder Kaur
- Dr. Bhagyalaxmi Nayak
- Dr. Somashekhar S.P
- Dr. Umesh Mahantshetty
- Dr. Rupinder Sekhon
- Dr. Yogesh Kulkarni





EUROPEAN SOCIETY OF PERITONEAL SURFACE ONCOLOGY



THE EUROPEAN SOCIETY
OF SURGICAL ONCOLOGY



THE EUROPEAN SOCIETY
OF SURGICAL ONCOLOGY



3rd INTERNATIONAL COURSE

WORKSHOP & CONFERENCE ON PERITONEAL SURFACE MALIGNANCIES YEAR IN REVIEW: GYNECOLOGIC ONCOLOGY | COLORECTAL CANCER

19 - 21 April 2019, Mumbai

SCIENTIFIC PROGRAM

Day 1, Friday 19 April 2019

07:45 - 08:15 REGISTRATION AND TEA/BREAKFAST

08:15 - 08:45 Welcome and Introduction

8:45 - 09:50 SESSION 1 : THE BASICS

08:45 - 09:00 Pathophysiology of Peritoneal Surface Malignancies

09:00 - 09:15 Anatomy of Peritoneal Cavity

09:15 - 09:30 Pharmacology of HIPEC

09:30 - 09:40 PCI, CCR, PSS: Getting Them Right

09:40 - 09:50 Q&A : Chairpersons & Speakers

09:50 - 11:25 SESSION 2 : THE TECHNIQUE

09:50 - 10:05 Achieving Optimal Cytoreduction: Tips and Tricks

10:05 - 10:20 Techniques of CRS and HIPEC: Dos & Don'ts


10:20 - 10:35 Setting up a CRS & HIPEC Program

10:35 - 10:50 Pathophysiology and approach to PMP and DMPM

10:50 - 11:00 Training and Fellowship Opportunities

11:00 - 11:10 Q&A : Chairpersons & Speakers

11:10 - 11:25 Tea/Coffee Break



EUROPEAN SOCIETY OF PERITONEAL SURFACE ONCOLOGY



THE EUROPEAN SOCIETY
OF SURGICAL ONCOLOGY



THE EUROPEAN SOCIETY
OF SURGICAL ONCOLOGY



3rd INTERNATIONAL COURSE

WORKSHOP & CONFERENCE ON PERITONEAL SURFACE MALIGNANCIES YEAR IN REVIEW: GYNECOLOGIC ONCOLOGY | COLORECTAL CANCER

19 - 21 April 2019, Mumbai

SCIENTIFIC PROGRAM

Day 1, Friday 19 April 2019

11:25 - 12:30 SESSION 3: VIDEOS: HOW I DO IT

- | | |
|---------------|--|
| 11:25 - 11:35 | Total Parietal Peritonectomy in Peritoneal Mesothelioma |
| 11:35 - 11:45 | Management of upper abdomen disease
<i>(Stripping of diaphragm, Splenectomy, Distal pancreatectomy and partial gastrectomy)</i> |
| 11:45 - 11:55 | Glisson Capsulectomy and Mesenteric Peritonectomy |
| 11:55 - 12:05 | Cytoreductive Surgery in Ovarian Cancer: Approach to pelvic disease |
| 12:05 - 12:15 | EPIC |
| 12:15 - 12:20 | IP port placement in ovarian cancer – Bard sponsored session (5 min) |
| 12:20 - 12:30 | Q&A : Chairpersons & Speakers |


12.30 - 1315 Lunch

13:15 - 17:30 SESSION 4 : LIVE SURGERY : CRC/HIPEC/PIPAC

- | | |
|---------------|----------------------|
| 13:15 - 17:30 | Moderators CRC HIPEC |
| 13:15 - 17:30 | Moderators CRC PIPAC |

13:15 - 17:30 SESSION 5 : WET LAB (WORKSHOP)

- | | |
|---------|--------------------------------|
| 15 mins | Science of energy |
| 15 mins | Science of anastomotic healing |



EUROPEAN SOCIETY OF PERITONEAL
SURFACE ONCOLOGY



THE EUROPEAN SOCIETY
OF SURGICAL ONCOLOGY



3rd INTERNATIONAL COURSE

WORKSHOP & CONFERENCE ON PERITONEAL SURFACE MALIGNANCIES

YEAR IN REVIEW: GYNECOLOGIC ONCOLOGY | COLORECTAL CANCER

19 - 21 April 2019, Mumbai

SCIENTIFIC PROGRAM

Day 1, Friday 19 April 2019


19:00 - 19:45 INDUSTRY SYMPOSIUM 1 - LILLY ONCOLOGY

19:45 - 20:30 INDUSTRY SYMPOSIUM 2 - MYLAN

19:45 - 20:00 Anti-Angeogenic Strategies for Advanced Gynecological Cancers

20:00 - 20:30 Panel Discussion : Selection of Optimal Biosimilar

20:30 Onwards Cultural Program and Dinner



EUROPEAN SOCIETY OF PERITONEAL SURFACE ONCOLOGY



THE EUROPEAN SOCIETY
OF SURGICAL ONCOLOGY



3rd INTERNATIONAL COURSE

WORKSHOP & CONFERENCE ON PERITONEAL SURFACE MALIGNANCIES YEAR IN REVIEW: GYNECOLOGIC ONCOLOGY | COLORECTAL CANCER

19 - 21 April 2019, Mumbai

SCIENTIFIC PROGRAM

Day 2, Saturday 20 April 2019

08:00 - 09:20 SESSION 6: PROFFERED PAPERS

08:00 - 09:00 Proffered Papers Presentation

09:00 - 09:20 PSOGI International Guidelines for Pseudomyxoma Peritonei and Mesothelioma

09:20 - 10:40 SESSION 7: CURRENT EVIDENCE FOR CRS & HIPEC IN COLORECTAL, GASTRIC & OVARIAN CANCERS

09:20 - 09:30 PRODIGE 7 & ProphylCHIP

09:30 - 09:40 COLOPEC & COMBATAC

09:40 - 09:50 GASTRIPEC & GASTRICHIP

09:50 - 10:00 OVHIPEC & TBD

10:00 - 10:40 **Panel Discussion:** Current evidence for CRS & HIPEC in Colorectal, gastric & ovarian cancers

10:40 - 11:00 Tea/Coffee Break

11:00 - 12:30 SESSION 8: TECHNICAL INTRICACIES OF CRS & HIPEC

11:00 - 11:35 **Panel Discussion:** Imaging and Laparoscopic Evaluation before CRS & HIPEC

11:35 - 11:50 Challenges in Anaesthetic Management in HIPEC

11:50 - 12:30 **HIPEC:** Procedural Nuances (Kidney protection- Sodium Thiosulphate, Ideal temperature, non-visible mets- ICG, prophylactic stoma)

12:30 - 13:00 CONFERENCE INAUGRATION



EUROPEAN SOCIETY OF PERITONEAL SURFACE ONCOLOGY



THE EUROPEAN SOCIETY
OF SURGICAL ONCOLOGY



ESSO
THE EUROPEAN SOCIETY
OF SURGICAL ONCOLOGY



3rd INTERNATIONAL COURSE

WORKSHOP & CONFERENCE ON PERITONEAL SURFACE MALIGNANCIES YEAR IN REVIEW: GYNECOLOGIC ONCOLOGY | COLORECTAL CANCER

19 - 21 April 2019, Mumbai

SCIENTIFIC PROGRAM

Day 2, Saturday 20 April 2019

13:00 - 13:45 Lunch Break

13:45 - 14:25 SESSION 9: CHEMOTHERAPY IN HIPEC

13:45 - 14:05 Chemotherapy Regimens in HIPEC

14:05 - 14:25 PIPAC: Rationale, Indications, Preliminary Outcomes
(Capnomed Sponsored Talk)

14:25 - 15:35 SESSION 10: ROAD TO ENHANCED RECOVERY

14:25 - 14:40 ERAS in Peritoneal Surface Malignancies
(Medtronic sponsored talk)

14:40 - 14:55 Supplemental PN in Surgical Patients
(Fresenius Kabi sponsored talk)

14:55 - 15:10 How to Reduce Post-Operative Complications?

15:10 - 15:25 Where are the dangers in HIPEC?

15:25 - 15:35 Q&A: Chairpersons & Speakers

15:35 - 15:50 Tea/Coffee Break

15:50 - 16:40 SESSION 11: INDIAN EXPERIENCE WITH HIPEC

15:50 - 16:00 Manipal Comprehensive Cancer Center, Bengaluru

16:00 - 16:10 Rajiv Gandhi Cancer Center, New Delhi

16:10 - 16:20 All India Institute of Medical Sciences, New Delhi



EUROPEAN SOCIETY OF PERITONEAL SURFACE ONCOLOGY



THE EUROPEAN SOCIETY
OF SURGICAL ONCOLOGY



THE EUROPEAN SOCIETY
OF SURGICAL ONCOLOGY



3rd INTERNATIONAL COURSE

WORKSHOP & CONFERENCE ON PERITONEAL SURFACE MALIGNANCIES YEAR IN REVIEW: GYNECOLOGIC ONCOLOGY | COLORECTAL CANCER

19 - 21 April 2019, Mumbai

SCIENTIFIC PROGRAM

Day 2, Saturday 20 April 2019

16:20 - 16:30 Fortis Memorial Research Institute, Gurugram

16:30 - 16:40 Indian RCT: Welcome Trial on IP and HIPEC

16:40 - 18:40 SESSION 12: INDUSTRY SYMPOSIUM

16:40 - 17:00 CORE DIAGNOSTICS

Genomics & next generation sequencing

17:00 - 17:50 ASTRAZENECA

PARP Inhibition in Ovarian Cancer


17:20 - 17:50 Panel Discussion

17:50 - 18:10 POSITIVE BIOSCIENCES/MYRIAD

BRCA testing – Indian scenario Myriad

18:10 - 18:40 ISPSM GBM

19:30 onwards Cultural Program and Dinner



Peritoneal Surface Oncology
PS GI
Group International

EUROPEAN SOCIETY OF PERITONEAL
SURFACE ONCOLOGY



THE EUROPEAN SOCIETY
OF SURGICAL ONCOLOGY



ESSO
THE EUROPEAN SOCIETY
OF SURGICAL ONCOLOGY



3rd INTERNATIONAL COURSE

WORKSHOP & CONFERENCE ON PERITONEAL SURFACE MALIGNANCIES YEAR IN REVIEW: GYNECOLOGIC ONCOLOGY | COLORECTAL CANCER

19 - 21 April 2019, Mumbai

SCIENTIFIC PROGRAM

The Year That Was (TYTW) - Gynecological Cancers

Day 3, Sunday 21 April 2019

— HALL A —

08:00 - 08:45 SESSION 13: QUIZ FOR PG STUDENTS

08:45 - 09:45 SESSION 14: PREVENTIVE AND PRIMARY CARE

08:45 - 08:55 **Abstract 1:** Linking cervicovaginal immune signatures, HPV and microbiota composition in cervical carcinogenesis in non-Hispanic and Hispanic women.

Laniewski P, et al., Sci Rep 2018; 8: 7593

Abstract 2: Relationship between the Cervical Microbiome, HIV Status and Precancerous Lesions.
Klein C, et al., MBio. 2019 Feb 19;10(1)

Abstract 3: Hand-to-genital and genital-to-genital transmission of human papillomaviruses between male and female sexual partners (HITCH): a prospective cohort study.
Talía Malagón et al., Lancet Infect Dis 2019


Abstract 4: Five-Year Risk of Cervical Precancer Following p16/Ki-67 Dual-Stain Triage of HPV-Positive Women.
Megan A. Clarke, et al., JAMA Oncol. 2019;5(2):181-186

Abstract 5: Performance of human papillomavirus testing on self-collected versus clinician-collected samples for the detection of cervical intraepithelial neoplasia of grade 2 or worse: a randomised, paired screen-positive, non-inferiority trial.
Nicole J Polman, et al., Lancet Oncol. 2019 Feb;20(2):229-238

08:55 - 09:05

Abstract 6: Trends in Human Papillomavirus Vaccine Types 16 and 18 in Cervical Precancers, 2008–2014

Nancy M. McClun, et al., Cancer Epidemiol Biomarkers Prev. 2019 Mar;28(3):602-609



EUROPEAN SOCIETY OF PERITONEAL SURFACE ONCOLOGY



THE EUROPEAN SOCIETY OF SURGICAL ONCOLOGY



THE EUROPEAN SOCIETY OF SURGICAL ONCOLOGY



3rd INTERNATIONAL COURSE

WORKSHOP & CONFERENCE ON PERITONEAL SURFACE MALIGNANCIES YEAR IN REVIEW: GYNECOLOGIC ONCOLOGY | COLORECTAL CANCER

19 - 21 April 2019, Mumbai

SCIENTIFIC PROGRAM

Day 3, Sunday 21 April 2019

- **Abstract 7:** Screening for Cervical Cancer: US Preventive Services Task Force Recommendation Statement.

Curry SJ, et al., JAMA. 2018 Aug 21;320(7):674-686

- **Abstract 8:** Screening for Cervical Cancer With High-Risk Human Papillomavirus Testing: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.

Melnikow J, et al., JAMA. 2018 Aug 21;320(7):687-705

09:05 - 09:15

- **Abstract 9:** Association Between Polycystic Ovary Syndrome and Cancer Risk.

Yin W1, et al., JAMA Oncol. 2019 Jan 1;5(1):106-107

- **Abstract 10:** Association between contemporary hormonal contraception and ovarian cancer in women of reproductive age in Denmark: prospective, nationwide cohort study.

Lisa Iversen, et al., BMJ. 2018 Sep 26;362:k3609

- **Abstract 11:** Risk of Malignant Ovarian Cancer Based on Ultrasonography Findings in a Large Unselected Population.

Smith-Bindman R, et al., JAMA Intern Med. 2019 Jan 1;179(1):71-77

- **Abstract 12:** Risk of complications in patients with conservatively managed ovarian tumours (IOTA5): a 2-year interim analysis of a multicentre, prospective, cohort study.


Froyman W, et al., Lancet Oncol. 2019 Mar;20(3):448-458

- **Abstract 13:** US Preventive Services Task Force Recommendation Statement. Screening for Ovarian Cancer

JAMA. 2018; 319(6):588-594

09:15 -09:45

- **Panel Discussion**



EUROPEAN SOCIETY OF PERITONEAL SURFACE ONCOLOGY



THE EUROPEAN SOCIETY OF SURGICAL ONCOLOGY



THE EUROPEAN SOCIETY OF SURGICAL ONCOLOGY



3rd INTERNATIONAL COURSE

WORKSHOP & CONFERENCE ON PERITONEAL SURFACE MALIGNANCIES YEAR IN REVIEW: GYNECOLOGIC ONCOLOGY | COLORECTAL CANCER

19 - 21 April 2019, Mumbai

SCIENTIFIC PROGRAM

Day 3, Sunday 21 April 2019

09:45 - 11:15

SESSION 15: OVARIAN CANCER

09:45 - 10:00

Abstract 1: Correlation between Surgeon's assessment and radiographic evaluation of residual disease in women with advanced stage ovarian cancer reported to have undergone optimal surgical cytoreduction: An NRG Oncology/Gynecologic Oncology Group study.
Ramez N. Eskander, et al., Gynecol Oncol. 2018 Jun;149(3):525-530

Abstract 2: A phase III randomized controlled trial of secondary surgical cytoreduction (SSC) followed by platinum-based combination chemotherapy (PBC), with or without bevacizumab (B) in platinum-sensitive, recurrent ovarian cancer (PSOC): A NRG Oncology/Gynecologic Oncology Group (GOG) study.
Robert L Coleman, et al., ASCO 2018, JCO.2018.36.15_suppl.5501


Abstract 3: A Randomized Trial of Lymphadenectomy in Patients with Advanced Ovarian Neoplasms.
Philipp Harter, et al., N Engl J Med. 2019 Feb 28;380(9):822-832

Abstract 4: Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer.
Willemien J. van Dier January 18, 2018. N Engl J Med 2018; 378:230-240

Abstract 5: Morbidity and Mortality Rates Following Cytoreductive Surgery Combined With Hyperthermic Intraperitoneal Chemotherapy Compared With Other High-Risk Surgical Oncology Procedures.
Foster JM, et al., JAMA Netw Open. 2019 Jan 4;2(1):e186847

10:00 - 10:10

Abstract 6: Survival analyses from a randomized trial of primary debulking surgery versus neoadjuvant chemotherapy for advanced epithelial ovarian cancer with high tumor load (SCORPION trial)
Anna Fagotti, et al., JCO 36, no. 15_suppl (May 20 2018) 5516-5516



EUROPEAN SOCIETY OF PERITONEAL SURFACE ONCOLOGY



THE EUROPEAN SOCIETY OF SURGICAL ONCOLOGY



3rd INTERNATIONAL COURSE

WORKSHOP & CONFERENCE ON PERITONEAL SURFACE MALIGNANCIES YEAR IN REVIEW: GYNECOLOGIC ONCOLOGY | COLORECTAL CANCER

19 - 21 April 2019, Mumbai

SCIENTIFIC PROGRAM

Day 3, Sunday 21 April 2019

Abstract 7: Comparison of survival between upfront primary debulking surgery versus neoadjuvant chemotherapy for stage III/IV ovarian, tubal and peritoneal cancers in phase III randomized trial: JCOG0602
Takachi Onda, et al., JCO 36, no. 15_suppl (May 20 2018) 5500-5500

Abstract 8: Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials.
Ignace Vergote, et al., Lancet Oncol. 2018 Dec;19(12):1680-1687

10:10 - 10:20

Abstract 9: AGO OVAR 2.21. A prospective randomized Phase III trial of Carboplatin / Gemcitabine / Bevacizumab vs. Carboplatin / Pegylated Liposomal Doxorubicin / Bevacizumab in patients with platinum-sensitive recurrent ovarian cancer. An ENGOT / GCIG Trial. ESMO 2018 Abstract 933O
J. Pfisterer, et al., Annals of Oncology (2018) 29 (suppl_8): viii332-viii358


Abstract 10: Alisertib in Combination With Weekly Paclitaxel in Patients With Advanced Breast Cancer or Recurrent Ovarian Cancer: A Randomized Clinical Trial.
Falchook G, et al., JAMA Oncol. 2019 Jan 1;5(1):e183773

Abstract 11: Paclitaxel With and Without Pazopanib for Persistent or Recurrent OvarianCancer: A Randomized Clinical Trial.
Debra L., et al., JAMA Oncol. 2018; 4(2):196-202

Abstract 12: Tumor Treating Fields in combination with paclitaxel in recurrent ovarian carcinoma: Results of the INNOVATE pilot study.
Vergote I, et al., Gynecol Oncol. 2018 Sep;150(3):471-477

10:20 - 10:30

Abstract 13: Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.
Moore K, et al., N Engl J Med. 2018 Dec 27;379(26):2495-2505



EUROPEAN SOCIETY OF PERITONEAL SURFACE ONCOLOGY



THE EUROPEAN SOCIETY
OF SURGICAL ONCOLOGY



ESSO
THE EUROPEAN SOCIETY
OF SURGICAL ONCOLOGY



3rd INTERNATIONAL COURSE

WORKSHOP & CONFERENCE ON PERITONEAL SURFACE MALIGNANCIES YEAR IN REVIEW: GYNECOLOGIC ONCOLOGY | COLORECTAL CANCER

19 - 21 April 2019, Mumbai

SCIENTIFIC PROGRAM

Day 3, Sunday 21 April 2019

- **Abstract 14:** Health-related quality of life and patient-centred outcomes with olaparib maintenance after chemotherapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT Ov-21): a placebo-controlled, phase 3 randomised trial

Michael Friedlander, et al., Lancet Oncol. 2018 Aug;19(8):1126-1134

- **Abstract 15:** Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16/NOVA): results from a double blind, phase 3, randomised controlled trial. *Lancet Oncol* 2018.

Amit M Oza, et al., Lancet Oncol. 2018 Aug;19(8):1117-1125

- **Abstract 16:** TOPACIO/Keynote-162 (NCT02657889): A phase 1/2 study of niraparib + pembrolizumab in patients (pts) with advanced triple-negative breast cancer or recurrent ovarian cancer (ROC)—Results from ROC cohort.

Panagiotis A, et al., ASCO 2018, Abstract 106.JCO 36, no. 15_suppl (May 20 2018) 106-106

10:30 - 10:40

- **Abstract 17:** BRCA Challenge: BRCA Exchange as a global resource for variants in BRCA1 and BRCA2.

Cline MS, et al., PLoS Genet. 2018 Dec 26;14(12):e1007752.

- **Abstract 18:** Accurate classification of BRCA1 variants with saturation genome editing.

Gregory M. Findlay, et al., Nature. 2018 Oct;562(7726):217-222

- **Abstract 19:** Molecular profiling of ovarian germ cell tumors.
M. Stasenko, et al., SGO 2018, Abstract 42

10:40 - 11:15

- **Panel Discussion**

11:15 - 11:30

- **TEA BREAK**



EUROPEAN SOCIETY OF PERITONEAL SURFACE ONCOLOGY



THE EUROPEAN SOCIETY OF SURGICAL ONCOLOGY



THE EUROPEAN SOCIETY OF SURGICAL ONCOLOGY



3rd INTERNATIONAL COURSE

WORKSHOP & CONFERENCE ON PERITONEAL SURFACE MALIGNANCIES YEAR IN REVIEW: GYNECOLOGIC ONCOLOGY | COLORECTAL CANCER

19 - 21 April 2019, Mumbai

SCIENTIFIC PROGRAM

Day 3, Sunday 21 April 2019

11:30 - 12:35

SESSION 16: UTERINE CANCER

11:30 - 11:45

- ☒ **Abstract 1:** Association of Endometrial Cancer Risk With Postmenopausal Bleeding in Women: A Systematic Review and Meta-analysis.

Clarke MA, et al., *JAMA Intern Med.* 2018 Sep 1;178(9):1210-1222

- ☒ **Abstract 2:** Evaluation of liquid from the Papanicolaou test and other liquid biopsies for the detection of endometrial and ovarian cancers. Wang Y, et al., *Sci Transl Med.* 2018 Mar 21;10(433)

- ☒ **Abstract 3:** Near-infrared fluorescence for detection of sentinel lymph nodes in women with cervical and uterine cancers (FILM): a randomised, phase 3, multicentre, non-inferiority trial. Frumovitz M, et al., *Lancet Oncol.* 2018 Oct;19(10):1394-1403

- ☒ **Abstract 4:** Sentinel lymph node (SLN) isolated tumor cells (ITCs) in otherwise stage I/II endometrioid endometrial cancer: To treat or not to treat? F.J. Backes, et al. *Gynecologic Oncology* 149:7-8.June 2018 (SGO 2018)

- ☒ **Abstract 5:** GOG 244, the lymphedema and gynecologic cancer (LEG) study: Incidence and risk factors in newly diagnosed patients. J.W. Carlsona, et al., Abstract 11, SGO 2018

11:45 - 11:55

- ☒ **Abstract 6:** Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial. PORTEC study group. de Boer SM, et al., *Lancet Oncol.* 2018 Mar;19(3):295-309

- ☒ **Abstract 7:** Patient-Reported Toxicity During Pelvic Intensity-Modulated Radiation Therapy: NRG Oncology-RTOG 1203. Klopp AH, et al., *J Clin Oncol.* 2018 Aug 20;36(24):2538-2544



EUROPEAN SOCIETY OF PERITONEAL SURFACE ONCOLOGY



THE EUROPEAN SOCIETY
OF SURGICAL ONCOLOGY



THE EUROPEAN SOCIETY
OF SURGICAL ONCOLOGY



3rd INTERNATIONAL COURSE

WORKSHOP & CONFERENCE ON PERITONEAL SURFACE MALIGNANCIES YEAR IN REVIEW: GYNECOLOGIC ONCOLOGY | COLORECTAL CANCER

19 - 21 April 2019, Mumbai

SCIENTIFIC PROGRAM

Day 3, Sunday 21 April 2019

11:55 - 12:05

- **Abstract 8:** Single-course methotrexate and single-course combined methotrexate–dactinomycin: A phase III randomized controlled clinical trial in treatment of low-risk gestational trophoblastic neoplasm.

L. Chena, et al., Gynecologic Oncology 149:20.June 2018.(SGO 2018)

- **Abstract 9:** The impact of uterine re-curettage on the number of chemotherapy courses in treatment of post molar gestational trophoblastic neoplasia: A randomized controlled study

R. Hemidaa, et al.,Abstract 41,SGO 2018

- **Abstract 10:** TROPHIMMUN, a 2 cohort phase II trial of the anti-PD-L1 monoclonal antibody avelumab in chemo-resistant gestational trophoblastic neoplasia (GTN) patients: preliminary outcomes in cohort A. L

You BM.et al.,BA35, ESMO 2018

12:05 - 12:35

- **Panel Discussion**

12:35 - 13:50

SESSION 17: CERVICAL CANCER


12:35 - 12:45

- **Abstract 1:** Revised FIGO staging for carcinoma of the cervix uteri. *Bhatla Net al.,Int J Gynaecol Obstet. 2019 Apr;145(1):129-135.*

- **Abstract 2:** High-risk human papillomavirus status and prognosis in invasive cervical cancer: A nationwide cohort study. *Lei J.,et al.,PLoS Med. 2018 Oct 1;15(10)*

- **Abstract 3:** Circulating Human Papillomavirus DNA as a Biomarker of Response in Patients With Locally Advanced Cervical Cancer Treated With Definitive Chemoradiation.

Kathy Han,et al.,JCO Precision Oncology - published online September 13, 2018



EUROPEAN SOCIETY OF PERITONEAL SURFACE ONCOLOGY



THE EUROPEAN SOCIETY
OF SURGICAL ONCOLOGY



ESSO
THE EUROPEAN SOCIETY
OF SURGICAL ONCOLOGY



3rd INTERNATIONAL COURSE

WORKSHOP & CONFERENCE ON PERITONEAL SURFACE MALIGNANCIES YEAR IN REVIEW: GYNECOLOGIC ONCOLOGY | COLORECTAL CANCER

19 - 21 April 2019, Mumbai

SCIENTIFIC PROGRAM

Day 3, Sunday 21 April 2019

12:45 - 12:55

■ ■ **Abstract 4:** LACC trial Minimally Invasive versus Abdominal Radical Hysterectomy for Cervical Cancer. November 15, 2018 *N Engl J Med* 2018. (To also integrate the LACC Abstract IGCS c/o AM & LACC Abstract IGCS c/o AM in the same presentation)
Pedro T. Ramirez, et al., N Engl J Med 2018; 379:1895-1904

■ ■ **Abstract 5:** Survival after minimally invasive radical hysterectomy for early-stage cervical cancer.
Melamed A, et al., N Engl J Med 2018;379:1905-1914


■ ■ **Abstract 6:** Outcomes and costs of open, laparoscopic and laparoscopic radical hysterectomy for stage 1B1 cervical cancer.
Margul DJ, et al., Journal of Clinical Oncology 36, no. 15_suppl (May 20 2018) 5502-5502.

■ ■ **Abstract 7:** Comparison of survival outcomes between minimally invasive surgery and conventional open surgery for radical hysterectomy as primary treatment in patients with stage IB1-IIA2 cervical cancer.
Kim SI, et al., Gynecol Oncol. 2019 Jan 12.

12:55- 13:10

■ ■ **Abstract 8:** Neoadjuvant Chemotherapy Followed by Radical Surgery Versus Concomitant Chemotherapy and Radiotherapy in Patients With Stage IB2, IIA, or IIB Squamous Cervical Cancer: A Randomized Controlled Trial.
Gupta S, et al. J Clin Oncol. 2018 Jun 1;36(16):1548-1555

■ ■ **Abstract 9:** Cisplatin Chemoradiotherapy vs Radiotherapy in FIGO Stage IIIB Squamous Cell Carcinoma of the Uterine Cervix: A Randomized Clinical Trial
Shrivastava S et al., JAMA Oncol. 2018 Apr 1;4(4):506-513



EUROPEAN SOCIETY OF PERITONEAL SURFACE ONCOLOGY



THE EUROPEAN SOCIETY
OF SURGICAL ONCOLOGY



THE EUROPEAN SOCIETY
OF SURGICAL ONCOLOGY



3rd INTERNATIONAL COURSE

WORKSHOP & CONFERENCE ON PERITONEAL SURFACE MALIGNANCIES YEAR IN REVIEW: GYNECOLOGIC ONCOLOGY | COLORECTAL CANCER

19 - 21 April 2019, Mumbai

SCIENTIFIC PROGRAM

Day 3, Sunday 21 April 2019

- **Abstract 10:** Randomized trial of adjuvant chemotherapy versus concurrent chemoradiotherapy in early-stage cervical cancer after radical surgery: A Chinese Gynecologic Oncology Group study (CSEM-002).

D. Wenga, et al. SGO 2018

- **Abstract 11:** Association of Definitive Pelvic Radiation Therapy With Survival Among Patients With Newly Diagnosed Metastatic Cervical Cancer.

Yuefeng Wang, et al., JAMA Oncol. 2018;4(9):1288-1291.

- **Abstract 12:** Pembrolizumab treatment of advanced cervical cancer: Updated results from the phase 2 KEYNOTE-158 study
Hyun Cheol Chung, et al., Journal of Clinical Oncology 36, no. 15_suppl (May 20 2018) 5522-5522

13:10 - 13:50

Panel Discussion


13:50 - 14:10

SESSION 18: RAPID REVIEW

13:50 - 14:00

- Association of Breast and Ovarian Cancers With Predisposition Genes Identified by Large-Scale Sequencing. Lu HM, Li S, Black MH, Lee S, Hoiness R, Wu S, Mu W, Huether R, Chen J, Sridhar S, Tian Y, McFarland R, Dolinsky J, Tippin Davis B, Mexal S, Dunlop C, Elliott A. JAMA Oncol. 2018 Aug 16.

Oral Contraceptive Use and Risks of Cancer in the NIH-AARP Diet and Health Study. Michels KA, Brinton LA, Pfeiffer RM, Trabert B. Am J Epidemiol. 2018 Aug 1;187(8):1630-1641



EUROPEAN SOCIETY OF PERITONEAL SURFACE ONCOLOGY



THE EUROPEAN SOCIETY
OF SURGICAL ONCOLOGY



esso
THE EUROPEAN SOCIETY
OF SURGICAL ONCOLOGY



3rd INTERNATIONAL COURSE

WORKSHOP & CONFERENCE ON PERITONEAL SURFACE MALIGNANCIES YEAR IN REVIEW: GYNECOLOGIC ONCOLOGY | COLORECTAL CANCER


19 - 21 April 2019, Mumbai

SCIENTIFIC PROGRAM

Day 3, Sunday 21 April 2019

14:00 - 14:10

- Hormone Replacement Therapy After Oophorectomy and Breast Cancer Risk Among BRCA1 Mutation Carriers. Kotsopoulos J, Gronwald J, Karlan BY, Huzarski T, Tung N, Moller P, Armel S, Lynch HT, Senter L, Eisen A, Singer CF, Foulkes WD, Jacobson MR, Sun P, Lubinski J, Narod SA; Hereditary Breast Cancer Clinical Study Group. *JAMA Oncol.* 2018 Aug 1;4(8):1059-1065
- Different menopausal hormone regimens and risk of breast cancer. Brusselaers N, Tamimi RM, Konings P, Rosner B, Adami HO, Lagergren J. *Ann Oncol.* 2018 Aug 1;29(8):1771-1776.
- Oncological management and obstetric and neonatal outcomes for women diagnosed with cancer during pregnancy: a 20-year international cohort study of 1170 patients. Jorine de Haan, Magali Verheecke, Kristel Van Calsteren, Ben Van Calsteren, Roman G Shmakov, Mina Mhallem Gziri, and others. *The Lancet Oncology*, Vol. 19, No. 3, p337-346
- Fertility Preservation in Patients With Cancer: ASCO Clinical Practice Guideline Update. Kutluk Oktay, Brittany E. Harvey, Ann H. Partridge, Gwendolyn P. Quinn, Joyce Reinecke, Hugh S. Taylor, W. Hamish Wallace, Erica T. Wang, Alison W. Loren. *JCO JUL 2018*
- Outpatient Talc Administration by Indwelling Pleural Catheter for Malignant Effusion Rahul Bhatnagar, Ph.D April 5, 2018 *N Engl J Med* 2018; 378:1313-1322
- Association Between Ultraprocessed Food Consumption and Risk of Mortality Among Middle-aged Adults in France. Schnabel L, Kesse-Guyot E, Allès B, Touvier M, Srour B, Hercberg S, Buscail C, Julia C. *JAMA Intern Med.* 2019 Feb 11.



EUROPEAN SOCIETY OF PERITONEAL SURFACE ONCOLOGY



THE EUROPEAN SOCIETY
OF SURGICAL ONCOLOGY



3rd INTERNATIONAL COURSE

WORKSHOP & CONFERENCE ON PERITONEAL SURFACE MALIGNANCIES YEAR IN REVIEW: GYNECOLOGIC ONCOLOGY | COLORECTAL CANCER

19 - 21 April 2019, Mumbai

SCIENTIFIC PROGRAM

Day 3, Sunday 21 April 2019

— HALL B —

08:00 - 14:30	SESSION 19: COTROVERSIES IN COLORECTAL CANCER
08.00 - 08:40	■ Free papers
08:40 - 09:10	■ Debate: CME (complete mesocolic excision) for colon cancer
09:10 - 09:40	■ Debate: Neoadjuvant chemotherapy and locally advanced colon cancer
09:40 - 10:10	■ Debate: Long course radiation Vs Short course radiation with 4 cycles chemotherapy
10:10 - 10:30	■ Molecular profiling & genomics in CRS + NGS technology – Whats new?
10:30 - 10:45	Tea/Coffee break
10:45 - 11:05	■ What is the way forward following the recent negative RCT's on CRS+HIPEC in colorectal cancer
11:05 - 11:20	■ Factors affecting Morbidity in HIPEC, analysis of 300 cases in Indian patients
11:20 - 11:30	■ Complete vs selective peritonectomy in peritoneal carcinomatosis secondary to CRC.
11:30 - 12:00	■ Debate: Consolidation chemotherapy in LARC who remain CRM positive after CTRT
12:00 - 12:30	■ Debate: Multiple resectable Liver metastasis and colon cancer: Neoadjuvant chemo vs. upfront surgery and adjuvant
12:30 - 12:45	■ Ovarian preservation in CRC



EUROPEAN SOCIETY OF PERITONEAL
SURFACE ONCOLOGY



THE EUROPEAN SOCIETY
OF SURGICAL ONCOLOGY



THE EUROPEAN SOCIETY
OF SURGICAL ONCOLOGY



3rd INTERNATIONAL COURSE


WORKSHOP & CONFERENCE ON PERITONEAL SURFACE MALIGNANCIES YEAR IN REVIEW: GYNECOLOGIC ONCOLOGY | COLORECTAL CANCER

19 - 21 April 2019, Mumbai

SCIENTIFIC PROGRAM

Day 3, Sunday 21 April 2019

12:45 - 13:00	■■■ Current Role of Robotic in colorectal surgery
13:00 - 13:30	■■■ Debate: Robotic rectum OR Laparoscopic rectal resection
13:30 - 14:00	■■■ Debate: T3 NO/ N1 rectum CRM free: upfront surgery Vs neoadjuvant therapy
14:00 - 14:15	■■■ Debate: Wait and watch for rectal cancer
14:15 Onwards	AWARD DISTRIBUTION & VALEDICTORY
14:30 Onwards	⌚ Lunch



EUROPEAN SOCIETY OF PERITONEAL
SURFACE ONCOLOGY



THE EUROPEAN SOCIETY
OF SURGICAL ONCOLOGY



THE EUROPEAN SOCIETY
OF SURGICAL ONCOLOGY



3rd INTERNATIONAL COURSE

WORKSHOP & CONFERENCE ON PERITONEAL SURFACE MALIGNANCIES YEAR IN REVIEW: GYNECOLOGIC ONCOLOGY | COLORECTAL CANCER

19 - 21 April 2019, Mumbai

REGISTRATION DETAILS

Only Workshop (19 April 2019)

Category	21 March 2019	22 March - 15 April 2019	Spot
ESSO/AGOI/ISPSM Members	2000	2500	—
Non-Members	3000	3500	—
Students & Trainees	1500	2000	—

Only Conference (20 - 21 April 2019)

Category	21 March 2019	22 March - 15 April 2019	Spot
ESSO/AGOI/ISPSM Members	3000	3500	5000
Non-Members	4000	4500	6000
Students & Trainees	1500	2000	3500

Workshop + Conference (19 - 21 April 2019)

Category	21 March 2019	22 March - 15 April 2019	Spot
ESSO/AGOI/ISPSM Members	4500	5500	—
Non-Members	6500	7500	—
Students & Trainees	2500	3500	—



EUROPEAN SOCIETY OF PERITONEAL
SURFACE ONCOLOGY



THE EUROPEAN SOCIETY
OF SURGICAL ONCOLOGY



3rd INTERNATIONAL COURSE

WORKSHOP & CONFERENCE ON PERITONEAL SURFACE MALIGNANCIES YEAR IN REVIEW: GYNECOLOGIC ONCOLOGY | COLORECTAL CANCER

19 - 21 April 2019, Mumbai

- For online registration visit our website: www.ispsm19.com

- Make NEFT on below details

Beneficiary name : ISPSM

Beneficiary Bank account No : 04852010065966

Beneficiary Bank Name : Syndicate Bank

Beneficiary Bank Branch : Manipal Hospital, Bangalore - 560017

IFSC code of Payee Bank : SYNB0000485

PAN No. : AABAI1853R

- For offline registration send a DD/Cheque in favor of "ISPSM" along with duly filled registration form to below address of conference secretariat.

Note:

- Cancellation with 75% refund will be entertained until 31 March 2019.
- After NEFT kindly send filled registration form to ispsm.agoi19@gmail.com

Conference Secretariat:

Anshul Bishnoi


RIVER ROUTE CREATIVE GROUP LLP

Unit No. 9, Cama Industrial Premises Co-op Society Ltd.

Sunmill Compound, Lower Parel (W), Mumbai - 400 013

Tel: +91 22 24931357/58 Email: ispsm.agoi19@gmail.com





EUROPEAN SOCIETY OF PERITONEAL
SURFACE ONCOLOGY



THE EUROPEAN SOCIETY
OF SURGICAL ONCOLOGY



3rd INTERNATIONAL COURSE

WORKSHOP & CONFERENCE ON PERITONEAL SURFACE MALIGNANCIES YEAR IN REVIEW: GYNECOLOGIC ONCOLOGY | COLORECTAL CANCER

19 - 21 April 2019, Mumbai

REGISTRATION FORM

Category

Member: Non - Member: Student/Trainee:

Only Workshop: Only Conference: Workshop + Conference:

AGOI/ISPSM Membership No.:

First Name: _____

Middle Name: _____

Last Name: _____

Mobile No: _____ Email id: _____

Hospital: _____

Department: _____ Specialization: _____

Postal Address: _____

City: _____ State: _____

Conference Secretariat:

Anshul Bishnoi

RIVER ROUTE CREATIVE GROUP LLP

Unit No. 9, Cama Industrial Premises Co-op Society Ltd.

Sunmill Compound, Lower Parel (W), Mumbai - 400 013

Tel: +91 22 24931357/58 Email: ispsm.agoi19@gmail.com

